Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 6/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.58 |
| ▸ | ATR | Q13535 | 13/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070857 | 0.87 | CYP4F2 (0.68) | CYP4F2CYP4A11ATRALDH1A1 | |
| SCHEMBL19277442 | 0.82 | CYP4F2 (0.64) | CYP4F2CYP4A11ATR | |
| SCHEMBL9977805 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11ATR | |
| SCHEMBL30509486 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11ATR | |
| SCHEMBL18034742 | 0.82 | CYP4F2 (0.57) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL21414800 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL19277056 | 0.80 | CYP4F2 (0.68) | CYP4F2CYP4A11ATR | |
| SCHEMBL9977842 | 0.80 | CYP4F2 (0.54) | CYP4F2CYP4A11ATR | |
| SCHEMBL19276681 | 0.80 | CYP4F2 (0.65) | CYP4F2CYP4A11ATR | |
| SCHEMBL13734367 | 0.78 | CYP4F2 (0.53) | CYP4F2CYP4A11ATRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327078-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117263945-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-113316578-B | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | CYP4F2 154/4885CYP4A11 3/4885ATR 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.